FOR RESEARCH USE ONLY. The content provided in this article is for educational and informational purposes only and is based on published scientific literature. The compounds discussed are not approved by the FDA for human or veterinary use. They are strictly intended for laboratory research and in vitro experimentation. Pure Health Peptides does not endorse or encourage the use of these products outside of a controlled research setting.
Semax and N-Acetyl Selank Amidate are two of the most studied peptides in neuropeptide research, and they are often considered side by side. They share a family resemblance, both are short, proline-rich synthetic peptides derived from natural sequences, but they come from different parent molecules and are studied through different pathways.
This article compares them: what each one is, the research profile of each, how their mechanisms and receptor themes differ, and where the N-Acetyl Amidate modification fits across the family.
Research Snapshot
- Semax is a synthetic heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro, engineered from the ACTH(4-10) fragment of adrenocorticotropin. Its molecular weight is approximately 813.9 g/mol.
- N-Acetyl Selank Amidate is a synthetic heptapeptide, Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2, an end-modified analog of Selank, which is itself derived from the immunopeptide tuftsin. Its molecular weight is approximately 792.9 g/mol.
- The two are studied through different primary pathways. Semax research centers on the neurotrophic factors BDNF and NGF (Shadrina et al., 2007). N-Acetyl Selank Amidate inherits the Selank research themes, which center on GABAergic signaling, enkephalin metabolism, and BDNF, associated with anxiolytic-pathway research in preclinical models.
- Both peptides share a stabilizing Pro-Gly-Pro motif, and N-Acetyl Selank Amidate adds N-terminal acetylation and C-terminal amidation on top of the Selank sequence, placing it within the N-Acetyl Amidate family of end-modified analogs.
- Pure Health Peptides supplies N-Acetyl Selank Amidate as a lyophilized Vial, and Semax as both a lyophilized Vial and an aqueous Liquid solution, part of the broader Pure Health Peptides catalog. Every lot is finished and tested in the USA, routed through independent, ISO/IEC 17025-accredited testing by Ethos Analytics as the exclusive testing partner.
The Two Compounds at a Glance
| Semax | N-Acetyl Selank Amidate | |
|---|---|---|
| Parent | ACTH(4-10) fragment of adrenocorticotropin | Tuftsin, via the Selank analog |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2 |
| Molecular weight | ~813.9 g/mol | ~792.9 g/mol |
| Terminal modifications | None (base peptide) | N-terminal acetyl, C-terminal amide |
| Primary research pathway | BDNF and NGF neurotrophic expression | GABAergic and enkephalin signaling, BDNF |
| Carrier formats | Vial, Liquid | Vial |
Semax: Mechanism and Research Profile
Semax is a synthetic heptapeptide engineered from the ACTH(4-10) fragment of adrenocorticotropin. The design replaced the C-terminal portion of the natural fragment with a Pro-Gly-Pro motif, a change that removes the corticotropic activity while preserving the neurotropic character and extending stability.
The result is a peptide with the neuro-relevant properties of the ACTH fragment but without the endocrine signaling.
In preclinical research, Semax is most associated with the neurotrophic factors. It has been characterized for increasing the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in nerve and glial cell systems and in rodent brain regions, with one study reporting regulation of BDNF and trkB expression in the rat hippocampus (Shadrina et al., 2007).
The effect on neurotrophic-factor expression is generally treated in the literature as the principal mechanism behind the neuroprotective properties attributed to the peptide. The Phase 1 Semax article covers the compound in more depth.
N-Acetyl Selank Amidate: Mechanism and Research Profile
N-Acetyl Selank Amidate comes from a different lineage. Its base, Selank, is a stabilized analog of tuftsin, an endogenous immunopeptide, extended with the same Pro-Gly-Pro motif that appears in Semax.
The N-Acetyl Selank Amidate form adds two terminal modifications, N-terminal acetylation and C-terminal amidation, which cap the ends of the peptide to slow enzymatic degradation, making it an end-modified analog studied for both its inherited pharmacology and its altered stability.
The research themes it inherits from Selank differ from those of Semax. Selank is characterized in preclinical work as an anxiolytic-pathway peptide, with reported modulation of GABAergic signaling and enkephalin metabolism alongside effects on BDNF, and reductions in anxiety-like behavior in rodent models.
Those themes carry into the acetylated, amidated analog. The Phase 1 N-Acetyl Selank Amidate article and the Selank article cover the family in more depth.
Comparing the Two: Pathways, Receptor Themes, and Research Applications
Placed side by side, Semax and N-Acetyl Selank Amidate are a study in family resemblance with distinct pharmacology. Structurally they rhyme: both are short heptapeptides, both are proline-rich, and both carry the stabilizing Pro-Gly-Pro tail. But their parents and their research pathways diverge.
Semax descends from an ACTH fragment and is studied primarily through neurotrophic-factor expression, the BDNF and NGF theme. N-Acetyl Selank Amidate descends from tuftsin through Selank and is studied primarily through anxiolytic-pathway biology, the GABAergic and enkephalin theme, with BDNF appearing on both sides as a shared point of contact.
For a researcher, that difference is the value of the comparison. A research question about neurotrophic-factor expression points toward Semax; a question about GABAergic or enkephalin-related signaling points toward the Selank lineage. The two are not substitutes but complementary tools within the same neuropeptide space, and studying them alongside each other is a way to contrast two different routes into cognitive and neuroregulatory pathway research.
The broader map for these compounds sits in the neuropeptides and cognitive signaling overview.
The N-Acetyl Amidate Modification Across the Family
One thread ties this comparison to a larger pattern. The N-terminal acetylation and C-terminal amidation seen on N-Acetyl Selank Amidate are not unique to it; they define a small family of end-modified research peptides that also includes the N-Acetyl Semax Amidate and N-Acetyl Epithalon Amidate analogs.
Each takes a well-characterized parent sequence, Selank, Semax, or Epithalon, and caps its termini to study how the modification affects stability. Viewed this way, the Semax versus N-Acetyl Selank comparison is really a comparison of two lineages, and the end-modified analogs let researchers examine each lineage in both its base and its capped form.
This comparison pairs naturally with the dedicated N-Acetyl Semax Amidate spotlight, which applies the same modification logic to the Semax side of the family.
Where This Comparison Sits in Neuropeptide Research
For researchers working across the neuropeptide space, Semax and N-Acetyl Selank Amidate mark two distinct but neighboring territories: a neurotrophic-factor lineage and an anxiolytic-pathway lineage, linked by shared structural motifs and a shared appearance of BDNF in the literature.
The value of the comparison is orientation, understanding which compound belongs to which research conversation, and how the N-Acetyl Amidate modification runs across both.
As research on these families continues, the comparison stays a useful entry point, connecting the individual deep-dives, the Selank spotlight, and the end-modified analogs into a single coherent cluster.
Frequently Asked Questions
What is the main difference between Semax and N-Acetyl Selank?
Semax is an ACTH(4-10)-derived heptapeptide studied mainly through the neurotrophic factors BDNF and NGF. N-Acetyl Selank Amidate is a tuftsin-derived, end-modified heptapeptide studied mainly through GABAergic and enkephalin signaling. They are related in structure but studied through different pathways.
Are Semax and Selank related?
They are both short, proline-rich synthetic peptides that share a stabilizing Pro-Gly-Pro motif, but they come from different parent molecules: Semax from an ACTH fragment, Selank from tuftsin.
What does the N-Acetyl Amidate modification do?
N-terminal acetylation and C-terminal amidation cap the ends of the peptide, the sites most exposed to the enzymes that degrade peptides from their termini. They are studied for their effect on stability across a family that also includes N-Acetyl Semax Amidate and N-Acetyl Epithalon Amidate.
Which compound is better for neuropeptide research?
Neither is universally better; they suit different research questions. Neurotrophic-factor questions point toward Semax; GABAergic and enkephalin-related questions point toward the Selank lineage.
What carrier formats are they available in, and how are they verified?
N-Acetyl Selank Amidate is supplied as a lyophilized vial. Semax is available as a lyophilized vial and an aqueous liquid solution. Every lot is finished and tested in the USA and routed through independent, ISO/IEC 17025-accredited testing by Ethos Analytics, with a lot-specific Certificate of Analysis published in the COA Library.
References
- Shadrina M, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 2007. https://www.sciencedirect.com/science/article/abs/pii/S0006899306022955
- Kolomin T, et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in Pharmacology, 2017. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2017.00089/full
- Selank, Peptide Analogue of Tuftsin, and BDNF regulation. Bulletin of Experimental Biology and Medicine, 2019. https://pubmed.ncbi.nlm.nih.gov/31625062/
- International Organization for Standardization / International Electrotechnical Commission. ISO/IEC 17025:2017, General requirements for the competence of testing and calibration laboratories. https://www.iso.org/standard/66912.html
